News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EKR Therapeutics, Inc. Names John E. Bailye New Chief Executive Officer


7/22/2010 10:31:39 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a privately held specialty pharmaceutical company focused on providing critical care products to the hospital marketplace, has announced a new senior management team designed to deliver growth in a challenging environment. The company’s Board of Directors has appointed John E. Bailye, 57, as its new Chief Executive Officer (CEO) and Bill McKee, 49, as its new Chief Operating Officer (COO). McKee will also serve as the company’s Chief Financial Officer (CFO). The executives assume their new positions immediately.

“We’re primed for growth because we have the best people, differentiated products and we know how to compete in the hospital market. We want to be the best at providing critical care, hospital based products that meet the needs of our customers and their patients.”

Bailye joined EKR Therapeutics in September 2009 as Executive Chairman. He is the founder and former Chairman of Dendrite International -- the firm that pioneered the development of software applications for pharmaceutical sales force management. Bailye spearheaded Dendrite’s growth from $175,000 in annual sales in 1987 to more than $420 million in 2006. The company was sold in 2007 for nearly $800 million. McKee joined EKR in June 2010 after a 15 year career with Barr Pharmaceuticals -- a leading generic pharmaceutical company acquired by Teva Pharmaceutical Industries Limited in 2008. His last position at Barr was Executive Vice President and Chief Financial Officer. During his tenure, Barr grew from a US-based generic pharmaceutical company with $60 million in revenue to a global, specialty pharmaceutical company with revenues of over $2.8 billion.

“This new leadership team offers a combination of pharmaceutical expertise and entrepreneurial spirit focused on helping the company achieve its full potential,” says Bailye. “We plan to leverage our experience with the current team that has achieved so much to ensure the future success of EKR.”

Since its inception, EKR has been commercializing products to address unmet and under-satisfied medical needs, enhancing the therapeutic value of acute-care products. The company has actively pursued opportunities to identify and foster the growth of specialty products that can significantly benefit from EKR’s knowledge and commercial strengths in the hospital space. With its experienced field force of sales professionals, along with its commitment to excellence in customer service and medical education, EKR is leading the way as a provider of acute-care specialty products.

“Our past achievements have created a strong foundation to help us realize our vision for the future,” says McKee. “Our long-standing relationships in the acute-care setting allow us to understand the hospital market in a way that makes EKR unique. As we’ve demonstrated with Ready-to-Use Cardene® IV, we are the experts in critical care; patient lives depend on our ability to educate our customers precisely about how our products can benefit patients.”

“By clarifying our long-term vision for the company, we hope to instill confidence that will motivate our employees to strive for excellence in everything they do,” Bailye adds. “We’re primed for growth because we have the best people, differentiated products and we know how to compete in the hospital market. We want to be the best at providing critical care, hospital based products that meet the needs of our customers and their patients.”

Headquartered in Bedminster, New Jersey, EKR Therapeutics is a specialty pharmaceutical company focused on the acute-care hospital setting. EKR is committed to serving the needs of this important segment of the healthcare market by providing novel products offering broader therapeutic potential and superior patient outcomes. Founded in late 2005 by veteran healthcare and business executives, EKR has brought together a highly cohesive team of pharmaceutical professionals with established records of accomplishments in acute care. A privately held company, EKR has investment support from leading venture capital and private equity firms. For additional information about EKR, visit the company’s website at www.ekrtx.com. Contacts

EKR Therapeutics Doug Petkus, 609-923-2838


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES